High triglycerides are one of the leading causes of pancreatitis, and for some people, extremely high levels can be caused by a rare genetic condition called Familial Chylomicronemia Syndrome (FCS).
We’re excited to share a new resource created for and by the FCS community in partnership with Arrowhead Pharmaceuticals. This was specifically designed for people and families affected by Familial Chylomicronemia Syndrome (FCS). The on-demand webinar, Managing Life with FCS: A Peer Support Toolbox, features individuals living with FCS and their caregivers talking about everyday challenges and sharing practical strategies for navigating life with this rare condition.
This resource is free, and you can gain access to it by registering at this link. Once signed up, you’ll have access to the full set of videos and tools.
What You’ll Find
The TalkingFCS.com webpage includes:
- Full-length On-Demand Webinar: Hear directly from peers about daily management, emotional well-being, and finding community.
- Short Topic Videos: Short, focused clips on specific themes
- Interactive Opportunity: Through Oct. 15, 2025, viewers can submit any non-medical questions to patientadvocacy@arrowheadpharma.com to be answered in an upcoming FCS Peer Support Toolbox Frequently Asked Questions (FAQ) resource.
This is a valuable opportunity to connect with individuals who are navigating this challenging and rare genetic disease and find guidance based on their experience in the form of peer support.
Why It Matters
Living with FCS can feel isolating, but hearing directly from others who understand can make a big difference. This resource provides encouragement, shared experience, and tools that help patients and caregivers feel less alone and more empowered.
Explore & Share
Visit www.TalkingFCS.com to explore the videos and resources, and we encourage you to share them with anyone who might benefit from these tools.
Learn More about FCS
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company developing a new therapy for familial chylomicronemia syndrome (FCS) that targets dangerously high triglyceride levels.
The company submitted a New Drug Application (NDA) for its FCS therapy in November 2024. The application is currently under review, with a decision expected by November 2025.
About Mission: Cure
At Mission: Cure, we are dedicated to finding effective treatments and, ultimately, a cure for pancreatitis. Through patient education, research, and advocacy, we strive to improve the lives of those affected by this condition.
Get Updates in Your Inbox
Stay up-to-date on the latest Mission: Cure news and developments in pancreatitis care by signing up for our newsletter.